Developing and Testing a Collaborative Quality ImProvement (C-QIP) Initiative for Prevention of Cardiovascular Disease in India
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Heart Disease
- Sponsor
- Public Health Foundation of India
- Enrollment
- 410
- Locations
- 4
- Primary Endpoint
- Prescription of evidence based medicines
- Status
- Completed
- Last Updated
- 3 months ago
Overview
Brief Summary
The overarching goal of this study is to develop, implement, and evaluate the effect of a collaborative quality improvement (C-QIP) intervention (consisting of non-physician health workers, text messages for a healthy lifestyle, and a clinical decision support system) on processes of care and clinical outcomes among individuals with previous cardiovascular disease in India.
Detailed Description
Specific objectives of this study are: 1. To describe current practices, context, challenges, and opportunities regarding chronic management of cardiovascular disease from the patient, caregiver, provider, and health administrator perspectives in India. 2. To assess the transferability of components of internationally successful multifaceted quality improvement strategies and chronic care models to the Indian healthcare context. 3. To conduct a pilot study to assess the acceptability, feasibility, and implementation fidelity of the C-QIP strategy among individuals with cardiovascular disease attending out-patient clinics in India. 4. Among individuals with cardiovascular disease, evaluate the effect of C-QIP strategy on processes of care and clinical outcomes, health-related quality of life, and costs at 1 year compared with usual care.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants should be:
- •age ≥18 years, both sexes
- •confirmed diagnosis of cardiovascular disease (ischemic heart disease, stroke, or heart failure irrespective of ejection fraction)
- •able to provide written informed consent.
Exclusion Criteria
- •pregnant women
- •those with any serious or uncontrolled medical condition (e.g., cancer) that may restrict the patient to come for follow-up.
Outcomes
Primary Outcomes
Prescription of evidence based medicines
Time Frame: at the end of study (maximum follow-up duration 24 months).
Through patient chart review, the study will assess the proportion of intervention arm versus control group participant's receiving evidence based medicines for cardiovascular disease management.
Implementation outcomes
Time Frame: at the end of study (maximum follow-up duration 24 months).
Using mixed methods evaluation involving quantitative survey and in-depth interviews with the providers and patients, the primary outcome of this study is to assess the implementation outcomes such as the feasibility, and acceptability of the trial intervention defined as the extent to which providers and patients perceive the intervention strategy to be feasible to implement and useful/acceptable in their local health care setting.
Adherence to prescribed therapy
Time Frame: at the end of study (maximum follow-up duration 24 months).
Using validated questionnaire for medication adherence, the study will assess patient's compliance or adherence to prescribed therapy in the intervention group versus control group participants at the trial end.
Secondary Outcomes
- Change in low density lipoprotein cholesterol (LDLc)(at the end of study (maximum follow-up duration 24 months).)
- Change in blood pressure(at the end of study (maximum follow-up duration 24 months).)